Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.410 +0.190 (+15.57%)
Official Closing Price Updated: 8:00 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial
Via Investor Brand Network
Topics Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Via ACCESS Newswire
News headline image
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $2 Million Registered Direct Offering
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
Via Investor Brand Network
Topics Intellectual Property
News headline image
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets
Via Investor Brand Network
Topics Intellectual Property
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering
Via Investor Brand Network
News headline image
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Via ACCESS Newswire
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident
Via Investor Brand Network
News headline image
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Participate in D. Boral Capital Global Conference
Via Investor Brand Network
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Orphan Drug Designation for NV-387
Via Investor Brand Network
News headline image
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment
Via Investor Brand Network
News headline image
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate
Via Investor Brand Network
News headline image
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA Investment Conference As NV-387 Oral Gummies Drug Supply Completed
Via Investor Brand Network
News headline image
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox
Via Investor Brand Network
Topics Intellectual Property
News headline image
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Via ACCESS Newswire
News headline image
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)
Via AB Newswire
Topics Death
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.